ResultsIQ

ResultsIQ › Latest results › Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Limited Q2 FY27 results press release summary

NSE: PGHH · BSE: 500459

Results press release of 12 Nov 2026, summarised by AI from the filing.

PGHH Q2 FY27 sales were ₹1145 cr, flat versus year ago, and PAT was ₹196 cr, down 7%.

Key takeaways

  1. Sales Q2 FY27 sales were ₹1145 cr, flat versus year ago.
  2. PAT Q2 FY27 PAT was ₹196 cr, down 7% versus year ago.
  3. Cost headwinds A double-digit impact on profitability came from commodity, raw material, energy and forex headwinds, partly offset by productivity.
  4. Investment The company continued to significantly invest back in innovation and advertising & promotion versus the past quarter.
  5. Risk Commodity cost fluctuations, raw material and energy costs and unfavorable foreign exchange rates weighed on profitability.

Original filing on BSE

Procter & Gamble Hygiene and Health Care Limited Q2 FY27 results

As filed: Revenue ₹1,145 cr (0% year on year), EBITDA ₹260 cr (−9% year on year), PAT ₹196 cr (−7% year on year), EBITDA margin 22.7% (−207 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹891 cr (−5% year on year), EBITDA ₹170 cr (−36% year on year), PAT ₹126 cr (−34% year on year), EBITDA margin 19.1% (−931 bps). Score 24 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 931 bps year on year. Revenue fell 5% from last quarter. Share price after the results: −9.8% in 30 days (Nifty 500: +1.8%).
  • Q4 FY26: Revenue ₹941 cr (−5% year on year), EBITDA ₹218 cr (+4% year on year), PAT ₹153 cr (−2% year on year), EBITDA margin 23.2% (+202 bps). Score 35 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 202 bps year on year. Revenue fell 25% from last quarter. Share price after the results: −10.8% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹1,262 cr (+1% year on year), EBITDA ₹402 cr (+8% year on year), PAT ₹301 cr (+12% year on year), EBITDA margin 31.8% (+211 bps). Score 45 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 211 bps year on year. Share price after the results: −4.7% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹1,150 cr (+1% year on year), EBITDA ₹285 cr (−2% year on year), PAT ₹210 cr (−1% year on year), EBITDA margin 24.8% (−77 bps). Score 40 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 77 bps year on year. Share price after the results: −6.1% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹937 cr (+1% year on year), EBITDA ₹266 cr (+125% year on year), PAT ₹192 cr (+137% year on year), EBITDA margin 28.4% (+1,000 bps). Score 73 of 100, Above trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 1000 bps year on year. Revenue fell 6% from last quarter. Share price after the results: 0.0% in 30 days (Nifty 500: −2.4%).
  • Q4 FY25: Revenue ₹992 cr (−1% year on year), EBITDA ₹210 cr (−18% year on year), PAT ₹156 cr (+1% year on year), EBITDA margin 21.2% (−448 bps). Score 34 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 448 bps year on year. Revenue fell 21% from last quarter. Share price after the results: +0.4% in 30 days (Nifty 500: +1.9%).
  • Q3 FY25: Revenue ₹1,248 cr (+10% year on year), EBITDA ₹371 cr (+20% year on year), PAT ₹269 cr (+17% year on year), EBITDA margin 29.7% (+237 bps). Score 67 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 237 bps year on year. Profit rose ₹40.0 cr on a year ago, more than the ₹22.0 cr it added the year before.

Past price moves after results do not indicate future moves. Not a recommendation.

Procter & Gamble Hygiene and Health Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.